Rare diseases present unique challenges when conducting clinical trials as a result of the small number of patients affected, and the heterogeneity of the population. Rare disease trials often amplify the challenges of designing a traditional trial, making it more difficult for developers to select treatment outcomes, gather payer evidence, and maintain patient interest.
Over the past 10 years, ICON’s highly experienced clinical and therapeutic teams have conducted numerous rare disease trials across a wide range of therapeutic areas, rendering us experts in the field. Learn more about the challenge of rare disease drug development, and how our experienced team can help you to navigate them.
To learn more about ICON, visit the website.